 AIM ImmunoTech Inc NYSE:AIM has revealed positive data evaluating Ampligen rintatolimod as a component of a regimen for the treatment of early-stage triple negative breast cancer. Led by by Roswell Park Comprehensive Cancer Center medical oncologist Dr Shipra Gandhi, the data will be presented in a poster presentation at the Society for Immunotherapy of Cancer 37th annual meeting being held virtually and in Boston, Massachusetts from November 8 to 12, 2022. 